Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review

References

• RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Nakhlband A, Fakhari A, Azizi H. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn-Schmiedeberg’s Arch Pharmacol. 2021 Feb;15:1.
   Google Scholar
• Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020 Aug 7;369(6504):718–724.
   PubMed Web of Science ®Google Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23;370:6515.
   Web of Science ®Google Scholar
• Dastan F, Nadji SA, Saffaei A, et al. Subcutaneous administration of interferon beta-1a for COVID-19: a non-controlled prospective trial. Int Immunopharmacol. 2020 Aug 1;85:106688.
   PubMed Web of Science ®Google Scholar
• Leonard T, Duffy JC. A Bayesian fixed effects analysis of the Mantel–Haenszel model applied to meta‐analysis. Stat Med. 2002 Aug 30;21(16):2295–2312.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986 Sep 1;7(3):177–188.
   PubMedGoogle Scholar
• Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006 Jun;11(2):193.
   PubMed Web of Science ®Google Scholar
• Harbord RM, Egger M, Sterne JA. A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Stat Med. 2006 Oct 30;25(20):3443–3457.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 Dec;1:1088–1101.
   Google Scholar
• Sterne JA, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. Bmj. 2001 Jul 14;323(7304):101–105.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001 Oct 1;54(10):1046–1055.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gonzalez CG, Chamorro-de-vega E, Valerio M, et al. COVID-19 in hospitalised patients in Spain: a cohort study in Madrid. Int J Antimicrob Agents. 2021 Feb 1;57(2):106249.
   Web of Science ®Google Scholar
• Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. Int Immunopharmacol. 2020 Nov 1;88:106903.
   PubMed Web of Science ®Google Scholar
• Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704.
   PubMed Web of Science ®Google Scholar
• Baghaei P, Dastan F, Marjani M, et al. Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. Int Immunopharmacol. 2021 Mar 1;92:107329.
   Web of Science ®Google Scholar
• Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020 Aug 20;64:9.
   Web of Science ®Google Scholar
• Gaibani P, Tonetti T, Bartoletti M, et al. Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: preliminary observations. J Glob Antimicrob Resist. 2021 Mar 1;24:124–126.
   Web of Science ®Google Scholar
• WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. N Engl J Med. 2021 Feb 11;384(6): 497–511.
   PubMed Web of Science ®Google Scholar
• Meffre E, Iwasaki A. Interferon deficiency can lead to severe COVID.
   Google Scholar
• Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 Oct 23;370:6515.
   Web of Science ®Google Scholar